Stacy R, et al. - Experts evaluated the clinical safety, tolerability, and efficacy of topically administered MGV354, a soluble guanylate cyclase (sGC) activator, in patients with ocular hypertension (OH) or glaucoma. As per the data, no statistically significant effect of MGV354 0.1% vs Vehicle in lowering IOP based on the study’s main outcome measure was seen. Ocular hyperemia was produced with MGV35 consistent with its pharmacology. Conjunctival and ocular hyperemia were the most common adverse events reported after MGV354 administration were conjunctival and ocular hyperemia.